Biogen’s BIIB080 Tau Reduction, SPINRAZA Approvals and Litifilimab Phase 3 Readouts
BIIB080 showed tau reductions in Phase 1b ahead of midyear cognition data, and high-dose SPINRAZA approval in US, Japan and Europe drove patient uptake. Biogen expects two SLE litifilimab Phase 3 readouts this year, sees CMS-backed blood biomarkers boosting LEQEMBI adoption and highlights SYFOVRE’s lesion-growth reduction data for geographic atrophy.
1. BIIB080 Development and Phase 1b Results
Biogen’s antisense oligonucleotide BIIB080 targets tau protein and achieved significant tau reductions in its Phase 1b trial. The data supported launching a proof-of-concept study to evaluate cognitive outcomes, with midyear results expected. The company is testing multiple dosing regimens to optimize treatment frequency and therapeutic levels.
2. SPINRAZA High-Dose Approval and Uptake
Biogen secured high-dose SPINRAZA approval in the US, Japan and Europe, expanding its rare disease portfolio. Initial feedback indicates strong patient and physician uptake across key markets. This approval is projected to bolster revenue in the current fiscal year given the unmet need in spinal muscular atrophy.
3. Litifilimab Phase 3 Trials and R&D Strategy
Two Phase 3 trials of SLE candidate litifilimab are on track to read out this year, with filing strategy contingent on the totality of positive and trending data. Leadership views external collaborations and internal R&D as complementary, focusing on late-stage pipeline assets while maintaining flexibility for opportunistic M&A post-Apellis acquisition.
4. Biomarkers and SYFOVRE Competitive Position
CMS approval of blood-based biomarkers for LEQEMBI confirmation is increasing adoption, and some clinicians are considering switching maintenance patients from Kisunla to LEQEMBI. In geographic atrophy, SYFOVRE has demonstrated significant lesion-growth reduction and long-term data supporting targeted ocular delivery, reinforcing its competitive positioning.